Get regular updates to your inbox.
Those who wish to gain practical tools for living optimally with rare diseases are encouraged to attend the annual Living Rare Living Stronger Patient and Family Forum, hosted by the National Organization for Rare Disorders (NORD) and set this year for June 26-27. The conference brings together patients,…
Read more
A wearable neurostimulation device developed by NeuroMetrix is being investigated in a Phase 2 clinical trial as a potential pain-relieving treatment for people with neuromyelitis optica spectrum disorder (NMOSD). The trial (NCT04614454) is expected to recruit 46 adult NMOSD participants who test positive for aquaporin-4 antibodies and…
Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…
Columnist Lelainia Lloyd shares about the shock she had in being subjected to ableism from a past care team.
NMOSD is a progressive autoimmune disease where the immune system mistakenly attacks nerve cells, affecting the nervous system. Learn more about the disease here.
Scientists do not know the exact underlying cause of NMOSD. Self-reactive antibodies that target AQP4 are known to play a major role. Learn more about what causes the disease here.
When the disease affects the optic nerve (optic neuritis), it can result in pain inside the eye and possibly blurry vision or vision loss. Learn more about the symptoms of the disease here.
Get regular updates to your inbox.
